Wockhardt’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, has been issued a Warning Letter by the US Food and Drug Administration (USFDA). Currently, there is no business being conducted from CP Pharmaceuticals to the US Market.
The company has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
